2018
Laser ablation after stereotactic radiosurgery: a multicenter prospective study in patients with metastatic brain tumors and radiation necrosis.
Ahluwalia M, Barnett GH, Deng D, Tatter SB, Laxton AW, Mohammadi AM, Leuthardt E, Chamoun R, Judy K, Asher A, Essig M, Dietrich J, Chiang VL. Laser ablation after stereotactic radiosurgery: a multicenter prospective study in patients with metastatic brain tumors and radiation necrosis. Journal Of Neurosurgery 2018, 130: 804-811. PMID: 29726782, DOI: 10.3171/2017.11.jns171273.Peer-Reviewed Original ResearchMeSH KeywordsAblation TechniquesAdultAgedBrain NeoplasmsFemaleHumansKarnofsky Performance StatusLaser TherapyMagnetic Resonance ImagingMaleMiddle AgedNecrosisNeoplasm Recurrence, LocalPostoperative ComplicationsProgression-Free SurvivalProspective StudiesQuality of LifeRadiation InjuriesRadiosurgeryTreatment OutcomeConceptsProgression-free survivalQuality of lifeKarnofsky Performance ScaleMulticenter prospective studyKPS scoreRecurrent tumorsStereotactic radiosurgeryOverall survivalProspective studyRadiation necrosisNeuro-Oncology Brain Metastases criteriaLocal progression-free survivalMedian KPS scoreSteroid sparing effectMetastatic brain tumorsLength of stayPercent of subjectsDuration of survivalOverall event rateSignificant differencesMajority of casesMetastasis (TNM) criteriaOS advantageProgression patientsBrain metastases
2013
The Use Of Donor Lymphocyte Infusion (DLI) For Relapse After Related T-Cell Replete HLA-Haploidentical Bone Marrow Transplantation (haploBMT) With Posttransplantation Cyclophosphamide (PTCy)
Zeidan A, Forde P, Symons H, Chen A, Smith B, Fuchs E, Luznik L, Jones R, Bolaños-Meade J. The Use Of Donor Lymphocyte Infusion (DLI) For Relapse After Related T-Cell Replete HLA-Haploidentical Bone Marrow Transplantation (haploBMT) With Posttransplantation Cyclophosphamide (PTCy). Blood 2013, 122: 4629. DOI: 10.1182/blood.v122.21.4629.4629.Peer-Reviewed Original ResearchDonor lymphocyte infusionPosttransplantation cyclophosphamideComplete responseGVHD prophylaxisMRD relapseLymphocyte infusionHematologic relapseCR rateDoses of DLIHLA-haploidentical bone marrow transplantationReasonable starting doseBone marrow transplantationDisease-specific criteriaOff-label useDuration of survivalAML ptsChronic GVHDAllogeneic BMTSevere graftStarting doseUnacceptable toxicityDonor chimerismMedian ageDisease relapseMarrow transplantation
2010
The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients
Wadia R, Stolar M, Grens C, Ehrlich B, Chao H. The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients. Oncotarget 2010, 5: 2-2. DOI: 10.18632/oncotarget.23441.Peer-Reviewed Original ResearchPeripheral neuropathyNeuronal calcium sensor-1Valproic acidSide effectsBipolar diseaseRetrospective chart review studyDose-limiting side effectChemotherapeutic drugsAltered calcium signalingDevelopment of CIPNPrevention of chemotherapyInitiation of chemotherapyMain dose-limiting side effectChart review studyRetrospective chart analysisVA electronic health recordMajor adverse effectsNumber of patientsDuration of survivalCalcium signalingHuman cancer patientsAberrant calcium signalingQuality of lifeElectronic health recordsApplication of drugs
2001
Preevaluation of Clinical Trial Data: The Case of Preemptive Cytomegalovirus Therapy in Patients with Human Immunodeficiency Virus
Paltiel A, Goldie S, Losina E, Weinstein M, Seage G, Kimmel A, Zhang H, Freedberg K. Preevaluation of Clinical Trial Data: The Case of Preemptive Cytomegalovirus Therapy in Patients with Human Immunodeficiency Virus. Clinical Infectious Diseases 2001, 32: 783-793. PMID: 11229847, DOI: 10.1086/319223.Peer-Reviewed Original ResearchMeSH KeywordsAIDS-Related Opportunistic InfectionsAntiviral AgentsChemopreventionCost-Benefit AnalysisCytomegalovirusCytomegalovirus InfectionsGanciclovirHIV InfectionsHumansModels, BiologicalPolymerase Chain ReactionPredictive Value of TestsQuality-Adjusted Life YearsSensitivity and SpecificityValganciclovirConceptsHuman immunodeficiency virusDuration of survivalPreemptive therapyCMV casesImmunodeficiency virusCMV polymerase chain reactionEnd-stage HIV diseaseUpcoming trialsCMV preemptive therapySalvage antiretroviral therapyCells/microLClinical trial dataCMV prophylaxisAntiretroviral therapyHIV diseaseComplication rateEfficacy assumptionsPolymerase chain reactionDisease progressionClinical uncertaintyDrug effectsPatientsTrial dataTherapyChain reaction
2000
Viability of HIV-1 in syringes: implications for interventions among injection drug users.
Heimer R, Abdala N. Viability of HIV-1 in syringes: implications for interventions among injection drug users. The AIDS Reader 2000, 10: 410-7. PMID: 10932845.Peer-Reviewed Original Research
1999
Survival of HIV-1 in Syringes
Abdala N, Stephens C, Griffith B, Heimer R. Survival of HIV-1 in Syringes. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1999, 20: 73-80. PMID: 9928733, DOI: 10.1097/00042560-199901010-00011.Peer-Reviewed Original Research
1997
Glutathione S-transferase class mu deletion polymorphism and breast cancer: results from prevalent versus incident cases.
Kelsey KT, Hankinson SE, Colditz GA, Springer K, Garcia-Closas M, Spiegelman D, Manson JE, Garland M, Stampfer MJ, Willett WC, Speizer FE, Hunter DJ. Glutathione S-transferase class mu deletion polymorphism and breast cancer: results from prevalent versus incident cases. Cancer Epidemiology Biomarkers & Prevention 1997, 6: 511-5. PMID: 9232338.Peer-Reviewed Original ResearchConceptsBreast cancerGene deletion polymorphismCase seriesDeletion polymorphismHealth StudyNull genotypeGSTM1 deletionGlutathione S-transferase class muPrevalent breast cancerIncident breast cancerNurses' Health StudyGSTM1 gene deletion polymorphismBreast cancer riskDuration of survivalAge-matched controlsGSTM1 null genotypeBreast cancer prognosisMolecular epidemiologic studiesImproved survivalCigarette smokingIncident casesOdds ratioPrevalent casesEpidemiologic studiesCancer risk
1996
Prolonged Survival in Patients with Advanced Melanoma Treated with Neoadjuvant Chemotherapy Followed by Resection
Sasson H, Poo W, Bakas M, Ariyan S. Prolonged Survival in Patients with Advanced Melanoma Treated with Neoadjuvant Chemotherapy Followed by Resection. Annals Of Plastic Surgery 1996, 37: 286-292. PMID: 8883727, DOI: 10.1097/00000637-199609000-00009.Peer-Reviewed Original ResearchConceptsStart of chemotherapySite of metastasisSurgical resectionPerformance statusResidual metastasesNeoadjuvant chemotherapyCombination chemotherapyMetastatic melanomaRetrospective analysisCompletion of chemotherapyCycles of chemotherapyConcomitant medical problemsDistant lymph nodesInitiation of therapySimilar clinical characteristicsTreatment of choiceNew combination regimensSignificant survival advantageDuration of survivalHigh response rateStable diseaseRecurrent diseaseClinical characteristicsMedian durationPartial response
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply